Processa Pharmaceuticals Inc Stock Price, News & Analysis

Processa Pharmaceuticals (NASDAQ: PCSA) will host a conference call on May 13, 2021, at 5:30 PM EST to discuss its Q1 2021 results and provide updates on its clinical pipeline. The call can be accessed via a toll-free number or an international line. The company focuses on developing products to improve survival and quality of life for patients with unmet medical needs, with active pipeline programs for conditions like metastatic colorectal cancer, breast cancer, and GI motility disorders.

Processa Pharmaceuticals reported significant progress in 2020, including the in-licensing of three programs with potential markets exceeding $1 billion each. The company anticipates dosing the first patients for PCS6422 and PCS499 in Q2 2021. Financial results show a net loss of $14.4 million, compared to $3.4 million in 2019. Processa's cash and equivalents stood at $15.4 million at year-end 2020, bolstered by recent fundraising totaling $27.3 million. Key upcoming milestones include FDA submissions and interim results for the ongoing clinical trials.

Processa Pharmaceuticals (NASDAQ: PCSA) will host a conference call on March 25, 2021, at 5:30 p.m. ET to discuss its fourth quarter 2020 results and clinical pipeline updates. Investors can join the call via a toll-free number or through a live webcast. Processa focuses on developing products for patients with unmet medical needs, with programs targeting cancers and gastrointestinal disorders. The company highlights its experienced development team, which has been involved with over 30 FDA drug approvals.

Processa Pharmaceuticals has selected 5 U.S. clinical sites for its Phase 2B trial of PCS499, aimed at treating ulcerative necrobiosis lipoidica. The trial, led by Dr. Misha Rosenbach, will evaluate the efficacy and safety of PCS499, with patient recruitment expected to start within 30-60 days. The condition affects the skin and can cause painful ulcerations, with no effective treatments currently available. Preliminary evaluations suggest PCS499 may close ulcers within months, which could significantly improve patient outcomes.

Processa Pharmaceuticals (Nasdaq: PCSA) has successfully closed a private placement raising $10.2 million by selling 1,321,132 shares at $7.75 each. The net proceeds amount to $9.9 million, which will finance clinical developments of PCS6422 and PCS11T through 2023. CEO David Young expressed gratitude to investors, highlighting the potential of these drugs in treating cancers such as colorectal and breast cancer. The offering was conducted under SEC exemptions, and a registration statement will be filed for resale of shares.

Processa Pharmaceuticals (NASDAQ: PCSA) announced a private investment in public equity (PIPE) financing, raising $10.2 million through the sale of 1,321,132 shares at $7.75 each. This financing, involving institutional and accredited investors, is expected to close around February 23, 2021, subject to customary conditions. The funds will support the advancement of their clinical pipeline, including studies in cancer and gastroparesis. CEO Dr. David Young expressed optimism about interim results from ongoing studies expected in the second half of 2021.

Processa Pharmaceuticals (NASDAQ: PCSA) announced its participation in two upcoming investor conferences, focusing on improving survival and quality of life for patients with unmet medical needs. The Craig-Hallum Alpha Select Virtual Conference will occur on November 17, 2020, while the Benchmark Annual Discovery 1x1 Investor Virtual Conference takes place on November 18, 2020. Interested parties can schedule one-on-one meetings with management through conference representatives. Processa's active pipeline includes treatments for metastatic colorectal cancer, breast cancer, and gastroparesis.

Processa Pharmaceuticals (PCSA) announced significant developments including a successful $19.2 million public offering and uplisting to Nasdaq. The company in-licensed two clinical drug candidates, PCS12852 and PCS6422, aimed at addressing unmet medical needs in gastrointestinal disorders and cancer treatments. Key future milestones include dosing patients in multiple clinical trials in 2021. Financially, Processa reported a net loss of $3.1 million for Q3 2020, but funds from the offering will support trials in markets exceeding $1 billion.

Processa Pharmaceuticals (NASDAQ: PCSA) announced a conference call on Nov. 12, 2020, at 5:30 p.m. ET to discuss its Q3 2020 results and provide updates on its clinical pipeline. The pipeline includes three drugs targeting significant markets: PCS6422 for cancer treatment, PCS499 for a rare condition called ulcerated necrobiosis lipoidica, and PCS12852 for GI motility issues like gastroparesis. A Q&A session with CEO David Young will follow the presentation. This event aims to showcase the company’s commitment to improving patient outcomes through innovative treatments.